Cerity Partners LLC Erasca, Inc. Transaction History
Cerity Partners LLC
- $55.1 Billion
- Q2 2025
A detailed history of Cerity Partners LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Cerity Partners LLC holds 57,817 shares of ERAS stock, worth $90,194. This represents 0.0% of its overall portfolio holdings.
Number of Shares
57,817
Previous 35,504
62.85%
Holding current value
$90,194
Previous $48,000
52.08%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ERAS
# of Institutions
157Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.6MShares$35.2 Million1.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$27 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$25.3 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$20.3 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$19.8 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $191M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...